Approaches to Conversations About Long-Acting Injectable Antipsychotics-Presentation Slides

Presentation Slides

Pdf Summary

This document is a collection of materials and resources related to conversations about long-acting injectable antipsychotics (LAIs). It is part of an initiative by the American Psychiatric Association (APA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) to support the clinical use of LAIs.<br /><br />The document includes information on the Clinical Support System for Serious Mental Illness (CSS-SMI), which is funded by SAMHSA and implemented by the APA. It also provides details on continuing education credits available for participants.<br /><br />The document includes faculty information and disclosures, as well as learning objectives for the initiative. It highlights existing research on the benefits and risks of LAIs and addresses patient and clinician perspectives on LAIs. It includes patient perceptions of LAIs, patient preferences, factors to consider for eligibility and selection, and clinician hesitancies about prescribing LAIs.<br /><br />The document also discusses the results of the PRELAPSE trial, which studied the use of aripiprazole monohydrate LAI in early-phase schizophrenia. It presents the study design, patient demographics, and outcomes, such as time to first hospitalization and secondary measures of hospitalizations and symptoms.<br /><br />The document provides information on shared decision-making and motivational interviewing in discussions about LAIs as a treatment option. It includes prepared scripts and role plays illustrating clinician-patient interactions about LAIs. It also addresses common concerns and challenges related to LAIs, such as treatment emergent side effects and adherence issues.<br /><br />The document concludes by outlining best practices for recommending LAIs, including strategies for talking about LAIs with young people and addressing family concerns. It emphasizes the importance of considering LAIs as an option for all patients and highlights the benefits of LAIs for patients, families, and healthcare providers.<br /><br />Overall, this document serves as a comprehensive resource for clinicians and healthcare professionals involved in conversations about LAIs as a treatment option for serious mental illness.

Keywords

Long-acting injectable antipsychotics

American Psychiatric Association

Substance Abuse and Mental Health Services Administration

Clinical Support System for Serious Mental Illness

Continuing education credits

Patient perceptions of LAIs

PRELAPSE trial

Aripiprazole monohydrate LAI

Shared decision-making

Motivational interviewing